Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EnteraBio's Oral Parathyroid Hormone (1-34)
EnteraBio's Parathyroid Hormone · 1 trial · 1 indication
safety will be measured by monitoring and recording adverse events related to hyper- and hypocalcemia
To study the pharmacokinetic profile of PTH absorption
| Arm | Type | Description |
|---|---|---|
| Oral Parathyroid Hormone (1-34) | EXPERIMENTAL | Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34) |
| Name | Type | Description |
|---|---|---|
| EnteraBio's Oral Parathyroid Hormone (1-34) | DRUG | Oral administration |
Inclusion Criteria: * Confirmed diagnosis of primary hypoparathyroidism for more than 1 year. * Currently taking \>1.0 grams of Calcium/day with a correlate alpha D3 dose. * 25(OH)D levels ≥ 20 ng/ml. * Signed informed consent. * BMI 18 - 30 kg/m2, inclusive. * Full blood count should be within the...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Ascendis Pharma A/S | ASND | 4 | PHASE3 | Palopegteriparatide |
| AstraZeneca PLC | AZN | 1 | PHASE3 | eneboparatide |
| MBX Biosciences, Inc. | MBX | 2 | PHASE3 | Canvuparatide |
| BridgeBio Pharma, Inc. | BBIO | 1 | PHASE3 | Encaleret |
EnteraBio's Parathyroid Hormone is being developed for the treatment of hypoparathyroidism, a condition in which the body produces insufficient parathyroid hormone. It is an oral formulation of parathyroid hormone (1-34) intended to replace the missing hormone. The drug is investigational and has been studied in a Phase 2 clinical trial.
EnteraBio's Parathyroid Hormone is being developed by Entera Bio Ltd., a clinical-stage biopharmaceutical company. Entera Bio Ltd. trades on the Nasdaq under the ticker symbol ENTX. The company focuses on oral peptide and protein therapeutics.
EnteraBio's Parathyroid Hormone is in Phase 2 clinical development. A Phase 2 pilot study has been completed. The drug is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
EnteraBio's Parathyroid Hormone has been studied in one completed clinical trial: NCT02152228, titled "A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism." This Phase 2 trial enrolled 20 participants in Israel and is now completed. No active trials are currently listed.
Yes, EnteraBio's Parathyroid Hormone is also known as EnteraBio's Oral Parathyroid Hormone (1-34). Both names refer to the same investigational oral formulation of parathyroid hormone (1-34) being developed by Entera Bio Ltd. for hypoparathyroidism.